Gallium radiopharmaceuticals 68
Main Article Content
Abstract
PET (positron emission tomography) is a technique of medical image of great sensibility and high resolution that requires short-lived positron emitting radionuclides. The most commonly used are and .The main difficulty of these radionuclides is the necessity to install a cyclotron in the site of use or not very far from it. Therefore convenient radionuclides have been researches, among them. The availability of this radionuclide from long-lived / generators, which can been used for along time far from the cyclotron location, and the rich coordination chemistry of have allowed to incorporate to the medical practice some radiopharmaceuticals as well as the research of a variety of stables complexes of coupled to biomolecules for diagnostic imaging of cancer and cardiovascular and neurological diseases. The present work is aimed at examining the potentialities of the - radiopharmacy.
Article Details
How to Cite
Morín Zorrilla, J., & Cruz Arencibia, J. (1). Gallium radiopharmaceuticals 68. Nucleus, (51). Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/557
Section
Panorama Nuclear
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
References
1.- BUCK AK, HERRMANN K, STARGARDT T, et. al. Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. J. Nucl. Med. Technol. 2010; 38: 6-17 doi: 10.2967/jnmt.108.059584
2.- BAUMAN G, BELHOCINE T, KOVACS M, et. al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15(1): 45-55. doi: 10.1038/pcan.2011.35.
3.- PAGANI M, STONE-ELANDER S, LARSSON SA. Alternative positron emission tomography with non-conventional positron emitters: effects on their physical properties on image quality and potential clinical applications; Eur. J. Nuc. Med. 1997; 24(10):1301-1327.
4.- BARTHOLOMÄ MD., LOUIE AS., VALLIANT JF., ZUBIETA J. Technetium and Gallium derived radiopharmaceuticals: Comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem.Rev. 2010; 110: 2903-2920.
5.-ZHERNOSEKOV KP, FILOSOFOV DV, BAUM RP, et. al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48: 1741-1748.
6.- International Atomic Energy Agency. Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods. Technical Report Series No 468. Vienna, IAEA, 2009.
7.-http://www2.chemistry.msu.edu/courses/CEM812/Hard_SoftAcid_Base.pdf
8.- JACKSON GE, BYRNE MJ. Metal Ion Speciation in Blood Plasma:Gallium-67-Citrate and MRJ Contrast Agent. J Nucl. Med. 1996; 37: 379-386.
9.- ANDERSON CJ, WELCH MJ. Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging. Chem. Rev. 1999, 99: 2219-2234.
10.- BERNSTEIN L. Mechanisms of Therapeutic Activity for Gallium. Pharmacological reviews. 1998; 50(4): 665-682.
11.- WELCH MJ, REDVANLY CS. Handbook of Radiopharmaceuticals, Radiochemistry and Applications. Chichester: John Miley & Sons Ltd, 2003.
12.- WADAS TJ, WONG EH, WEISMAN GR, ANDERSON CJ. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem. Rev. 2010; 110: 2858-2902.
13.- DI CARLI MF, DORBALA S. Cardiac PET-CT. J Thorac Imaging. 2007; 22: 101-106.
14.- PLÖSSLA K, CHANDRAA R, QUA W, et. al. A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent. Nucl. Med. and Biology. 2008; 35: 83-90.
15.- HSIAO YM, MATHIAS CJ, WEY SP, et. al. Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N?-bis(3-aminopropyl)-N,N?-dimethylethylenediamine:potential agents for PET myocardial imaging with 68Ga. Nucl Med Biol. 2009; 36:39-45.
16.-TAKAHIRO M, JUN S, KOHEI S, et. al. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: Two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability. Bioorg. Med. Chem. 2009; 17: 4285-4289.
17.- TAN EH, GOH SW. Exploring new frontiers in molecular imaging: Emergence of 68Ga PET/CT. World J Radiol. 2010; 28 (2): 55-67.
18.- HOFMANN M, MAECKE H, BORNER A, et. al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Me. 2001; 28: 1751-1757.
19.- GABRIEL M, DECRISTOFORO C, KENDLER D, et. al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J Nucl Med. 2007; 48: 508-518.
20.- BAUM R. Ga-68 Labelled Radiopharmaceuticals for Molecular Imaging of Cancer Using PET/CT - Present State and Future Perspectives. [document en línea]2010 http://www.singaporeradiology2010.com/programme_detailed.pdf.
21.- DECRISTOFORO C, HERNÁNDEZ I, CARLSEN J, et. al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of integrin expression. Eur J. Nucl. Med. Mol. Imaging. 2008; 35: 1507-1515.
22.- HAUBNER R, WESTER HJ, WEBER WA, et, al. Noninvasive imaging of integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61: 1781-1785.
23.- VELIKYAN I. Synthesis, Characterization and Application of 68Ga-labelled Peptides and Oligonucleotides [Thesis for the filosofie licentiate degree] Department of Organic Chemistry, Institute of Chemistry, UPPSALA UNIVERSITY. January 2004
24.- ZIBO L, CONTI PS. Radiopharmaceutical chemistry for positron emission tomography. Advanced drug delivery reviews. 2010; 62(11): 1031-1051.
2.- BAUMAN G, BELHOCINE T, KOVACS M, et. al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15(1): 45-55. doi: 10.1038/pcan.2011.35.
3.- PAGANI M, STONE-ELANDER S, LARSSON SA. Alternative positron emission tomography with non-conventional positron emitters: effects on their physical properties on image quality and potential clinical applications; Eur. J. Nuc. Med. 1997; 24(10):1301-1327.
4.- BARTHOLOMÄ MD., LOUIE AS., VALLIANT JF., ZUBIETA J. Technetium and Gallium derived radiopharmaceuticals: Comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem.Rev. 2010; 110: 2903-2920.
5.-ZHERNOSEKOV KP, FILOSOFOV DV, BAUM RP, et. al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48: 1741-1748.
6.- International Atomic Energy Agency. Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods. Technical Report Series No 468. Vienna, IAEA, 2009.
7.-http://www2.chemistry.msu.edu/courses/CEM812/Hard_SoftAcid_Base.pdf
8.- JACKSON GE, BYRNE MJ. Metal Ion Speciation in Blood Plasma:Gallium-67-Citrate and MRJ Contrast Agent. J Nucl. Med. 1996; 37: 379-386.
9.- ANDERSON CJ, WELCH MJ. Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging. Chem. Rev. 1999, 99: 2219-2234.
10.- BERNSTEIN L. Mechanisms of Therapeutic Activity for Gallium. Pharmacological reviews. 1998; 50(4): 665-682.
11.- WELCH MJ, REDVANLY CS. Handbook of Radiopharmaceuticals, Radiochemistry and Applications. Chichester: John Miley & Sons Ltd, 2003.
12.- WADAS TJ, WONG EH, WEISMAN GR, ANDERSON CJ. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem. Rev. 2010; 110: 2858-2902.
13.- DI CARLI MF, DORBALA S. Cardiac PET-CT. J Thorac Imaging. 2007; 22: 101-106.
14.- PLÖSSLA K, CHANDRAA R, QUA W, et. al. A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent. Nucl. Med. and Biology. 2008; 35: 83-90.
15.- HSIAO YM, MATHIAS CJ, WEY SP, et. al. Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N?-bis(3-aminopropyl)-N,N?-dimethylethylenediamine:potential agents for PET myocardial imaging with 68Ga. Nucl Med Biol. 2009; 36:39-45.
16.-TAKAHIRO M, JUN S, KOHEI S, et. al. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: Two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability. Bioorg. Med. Chem. 2009; 17: 4285-4289.
17.- TAN EH, GOH SW. Exploring new frontiers in molecular imaging: Emergence of 68Ga PET/CT. World J Radiol. 2010; 28 (2): 55-67.
18.- HOFMANN M, MAECKE H, BORNER A, et. al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Me. 2001; 28: 1751-1757.
19.- GABRIEL M, DECRISTOFORO C, KENDLER D, et. al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J Nucl Med. 2007; 48: 508-518.
20.- BAUM R. Ga-68 Labelled Radiopharmaceuticals for Molecular Imaging of Cancer Using PET/CT - Present State and Future Perspectives. [document en línea]2010 http://www.singaporeradiology2010.com/programme_detailed.pdf.
21.- DECRISTOFORO C, HERNÁNDEZ I, CARLSEN J, et. al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of integrin expression. Eur J. Nucl. Med. Mol. Imaging. 2008; 35: 1507-1515.
22.- HAUBNER R, WESTER HJ, WEBER WA, et, al. Noninvasive imaging of integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61: 1781-1785.
23.- VELIKYAN I. Synthesis, Characterization and Application of 68Ga-labelled Peptides and Oligonucleotides [Thesis for the filosofie licentiate degree] Department of Organic Chemistry, Institute of Chemistry, UPPSALA UNIVERSITY. January 2004
24.- ZIBO L, CONTI PS. Radiopharmaceutical chemistry for positron emission tomography. Advanced drug delivery reviews. 2010; 62(11): 1031-1051.